ArticleBiology direct2026

MEF2A activates the ZDHHC20/NF-κB pathway to inhibit doxorubicin sensitivity and promote the malignant progression of acute myeloid leukemia.

Xi Ming et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.